YEAR EVENTS 1962 - The Company was incorporated on 22nd August, at Bombay. - The Company manufactures pharmaceutical products and chemicals on behalf of Uni-U.C.B.(India) Pvt.Ltd., associates of the reputed UCB of Brussels, Belgium. - Government approved the scheme to manufacture dextran and iron dextran cycoside in collaboration with Roshkilde Medical Company of Denmark. - Government also approved the Collaboration Scheme with Shofu Dental Mfg.Co.Ltd., Japan, for the manufacture of dental products. - The Company was formed to take over as a going concern the propreitory business carried on since 1944, at Bombay, by Shri A V Mody as manufacturing chemist and dealer in pharmaceuticals and medicines, under the name and style of 'Unichem Laboratories'. 1983 - The Upjohn division was established, the name was changed to UNISEARCH division with effect from 1st October, 1987. This was to market selected specialities of Upjohn, UCB and Unichem. 1992 - Unichem Exports Limited ceased to be a subsidiary of the company from 17th November. 1993 - The Company introduced a new antibiotic in the market, and incurred substantial cost on the new launch. 1994 - The Company made an Issue of Equity Shares to the shareholders, promoters and employees as a result of which the Equity share Capital has increased to Rs.199.12 lacs. 1995 - The Pharma Division extended its products range by launching two new molecules and one additional formulation in the market. - 5,59,900 No. of Equity Warrants were allotted to th Promoters/Promoter Group. 1998 - The Company has launched three new products in three different therapeutic areas i.e. Cardiovascular, Anti Inflammatory and Anti oxidant under the brand names CORVADIL-A, PRONIM and PRO-RIDAGE. - The company has a technical collaboration with Shofu Dental Manufacturing Co, Japan and Roshkilde Medical Co, Denmark. - The Company has launched three new products in three different therapeutic areas viz., Satin a cholesterol reducer in the area of cardiovascular therapeutic segment; Domadol in the post operative pain management segment and Zonep in the psychiatry segment. - The company recently commissioned a Rs 20-crore manufacturing facility at Bardez in Goa, specially designed to meet stringent standards in export markets. 1999 - The Company's new Division mainly catering to Women's Healthcare called "FOREVA" was launched on 1st April. - The Company has launched eight new products, Losar, Serta, Biclar, Zisper, M-cam, Flospar, Lanpro, Anticox 3. - Unichem Laboratories, a leading pharmaceutical company, has launched `M-Cam', a non-steroidal anti-inflammatory drug (NSAID) for the treatment or arthritis. - The company has recently commissioned its multi-purpose facility at Roha in Maharashtra to manufacture a range of bulk drugs scheduled to go off patent in advanced markets by 2000. - The company has tied up with Aptech and NIIT to reach a majority of the nearly 3,000 cardiologists and over 20,000 physician MDs in the country. 2000 - Unichem Laboratories has entered into a strategic alliance with the Korean Green Cross Corporation to market Urokinase. - The Company has introduced "Celib" for management of arthritis. The Company has launched a website on Celib for doctors and patients called www.celibunichem.com. - Unichem Laboratories has launched Zulu, the first muscle relaxant containing nimesulide and tizanidine. - The Foreva, the Women's healthcare division of the company has acquired the marketing and distribution rights for Partobulin (Anti-D Immunoglobulin) in India from Baxter Healthcare. - The Company will launch its own version of Pfizer's impotence pill Viagra under the brand name Erix. 2001 - Foreva, the women's healthcare division of Unichem Laboratories, has entered into a technical tie-up with the US-based Protein Technologies International Inc, a DuPont division, for developing a soya protein supplement for women called Nutreva. 2002 -Enters into Joint Venture with the former Directors of the Bioglan group in Ireland. -Bharat Bio signs marketing alliance with the company to market hepatitis-B, recombinant. -Ind-Swift ties up with the company for Co-marketing pact to co-market finished dosages of its anti-depressant drug citalopram 2003 -Registered a net profit increase by around 10.6% in the I quarter at Rs.9.4crs for the same period last year. -Enters into an agreement for the sale of its Animal Healthcare Division to M/s Tetragon Chemie Ltd. -Appoints Mr Prafful D Sheth as the Director of the company. -Unichem Laboratories Ltd, a Mumbai based Rs 475-crore pharmaceutical company, has received ISO 9001 & 14001 certificates - On April 20, 2005 announces commencement of production at its second unit at Baddi, Himachal Pradesh. 2006 -Unichem Laboratories enters into agreement with PLIVA inc, USA 2009 - Unichem Laboratories Ltd has appointed Mr. Harcharan Singh as Chief Executive - Pharma with effect from March 24, 2009. He shall report to the Board. 2010 -Unichem Laboratories Ltd has received approval from US Food & Drug Administration (U.S. FDA) for Hydrochlorothiazide Capsules in the strengths of 12.5 mg. -Unichem Laboratories Ltd strengthened 6.38% to close at Rs 381.15 as the company has received EU GMP certificate from IRISH Medicines Board for the 12 API's manufactured at Company's Roha plant. -Company has splits its Face value of Shares from Rs 5 to Rs 2 2011 -Unichem Laboratories Ltd has received approval from US Food & Drug Administration (FDA) for Divalproex Sodium Delayed Release Tablets USP 125mg, 250mg and 500mg (Valproic -Acid Activity). 2012 -Mr. Bhagwat S. Dhingra has been appointed as Chief Executive - Domestic Pharma. -"Unichem Laboratories receives ANDA tentative approval from USFDA for IRBESARTAN TABLETS". -Unichem gets tentative nod from USFDA for dementia tablets. 2013 -"Unichem Laboratories receives ANDA approval from USFDA for Amlodipine Besylate Tablets". -Unichem Laboratories has recommended Dividend of Rs. 4.50 (225%) per equity share of Rs. 2/- each. 2014 -"Unichem Laboratories receives ANDA approval from USFDA for Metronidazole USP Tablets". -Unichem Laboratories has recommended Final Dividend of Rs. 4/- (200%) per equity share of Rs. 2/- each . 2015 - Unichem bags ANDA approval for Montelukast Sodium tablets -Acquired API manufacturing unit at Kolhapur -Commissioned expanded capacities at Goa plant 2017 -Divested domestic formulation business to Torrent Pharma 2019 -Strategic investment in Hyderabad based Optimus Drugs Pvt Ltd. & Optrix Laboratories Pvt Ltd. -New plant site acquired in Goa -Product facility expansions in Ghaziabad and Pithampur 2020 -Unichem Laboratories gets USFDA nod to market generic version of tolterodine tartrate tablets. 2021 -Unichem Laboratories receives USFDA approval for Aripiraprazole tablets. -Unichem Laboratories receives USFDA approval for Zonisamide Capsules. -Unichem Laboratories gets USFDA nod for plaque psoriasis treatment drug. -New Oral Solid Dosage manufacturing facility commissioned at Goa Plant II. 2022 -Unichem Laboratories receives ANDA approval for Extended Phenytoin Sodium Capsules. -Unichem Labs gets US FDA nod for Schizophrenia drug. 2023 -Ipca Laboratories Limited acquires 52.67% of the paid-up share capital of Unichem